Free Trial

Beam Therapeutics (BEAM) News Today

Beam Therapeutics logo
$15.84 -3.98 (-20.10%)
As of 02:30 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
Beam Therapeutics Inc. stock logo
Renaissance Technologies LLC Makes New $568,000 Investment in Beam Therapeutics Inc. (NASDAQ:BEAM)
Renaissance Technologies LLC purchased a new stake in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 22,907 shares of the company's stock, valued at approxi
Beam Therapeutics Inc. stock logo
ARCH Venture Management LLC Sells 294,521 Shares of Beam Therapeutics Inc. (NASDAQ:BEAM)
ARCH Venture Management LLC lessened its holdings in shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 6.1% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 4,540,132 shares of the company's stock after selling 2
Beam Therapeutics Inc. stock logo
Susquehanna Fundamental Investments LLC Acquires New Shares in Beam Therapeutics Inc. (NASDAQ:BEAM)
Susquehanna Fundamental Investments LLC acquired a new position in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 52,725 shares of the company's stock, val
Beam Therapeutics Inc. stock logo
Beam Therapeutics Inc. (NASDAQ:BEAM) Short Interest Update
Beam Therapeutics Inc. (NASDAQ:BEAM - Get Free Report) was the recipient of a significant increase in short interest in the month of April. As of April 15th, there was short interest totalling 18,830,000 shares, an increase of 27.7% from the March 31st total of 14,740,000 shares. Based on an average daily trading volume, of 2,120,000 shares, the short-interest ratio is currently 8.9 days. Approximately 23.7% of the company's shares are sold short.
Beam Therapeutics Inc. stock logo
Price T Rowe Associates Inc. MD Purchases 266,834 Shares of Beam Therapeutics Inc. (NASDAQ:BEAM)
Price T Rowe Associates Inc. MD raised its position in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 18.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,753,142 shares of the company's stock after purchasing an
Beam Therapeutics Inc. stock logo
Beam Therapeutics (BEAM) Projected to Post Quarterly Earnings on Tuesday
Beam Therapeutics (NASDAQ:BEAM) will be releasing its Q1 2025 earnings before the market opens on Tuesday, May 6. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-6-beam-therapeutics-inc-stock/)
Beam Therapeutics Inc. stock logo
Marshall Wace LLP Buys Shares of 55,000 Beam Therapeutics Inc. (NASDAQ:BEAM)
Marshall Wace LLP bought a new stake in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm bought 55,000 shares of the company's stock, valued at approximately $1,364,000. Marshall Wace LLP owned 0.07% of Be
Beam Therapeutics Inc. stock logo
Beam Therapeutics Inc. (NASDAQ:BEAM) Receives Consensus Rating of "Buy" from Brokerages
Beam Therapeutics Inc. (NASDAQ:BEAM - Get Free Report) has received an average recommendation of "Buy" from the fourteen brokerages that are currently covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and t
Beam Therapeutics Inc. stock logo
Barclays PLC Increases Stock Holdings in Beam Therapeutics Inc. (NASDAQ:BEAM)
Barclays PLC boosted its stake in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 51.7% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 278,019 shares of the company's stock after buying an additional 94,805 shares during
Beam Therapeutics Inc. stock logo
Wells Fargo & Company MN Has $3.17 Million Position in Beam Therapeutics Inc. (NASDAQ:BEAM)
Wells Fargo & Company MN grew its position in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 17.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 128,002 shares of the company's stock after acqui
Beam Therapeutics Inc. stock logo
Beam Therapeutics Target of Unusually High Options Trading (NASDAQ:BEAM)
Beam Therapeutics Inc. (NASDAQ:BEAM - Get Free Report) was the recipient of unusually large options trading on Tuesday. Traders acquired 10,060 put options on the stock. This is an increase of 1,089% compared to the typical volume of 846 put options.
Beam Therapeutics Inc. stock logo
Beam Therapeutics (NASDAQ:BEAM) Stock Price Up 5.5% - Still a Buy?
Beam Therapeutics (NASDAQ:BEAM) Trading 5.5% Higher - Here's What Happened
Beam Therapeutics Inc. stock logo
Beam Therapeutics Inc. (NASDAQ:BEAM) Sees Significant Growth in Short Interest
Beam Therapeutics Inc. (NASDAQ:BEAM - Get Free Report) was the target of a significant increase in short interest in March. As of March 31st, there was short interest totalling 14,740,000 shares, an increase of 21.2% from the March 15th total of 12,160,000 shares. Currently, 18.6% of the company's stock are short sold. Based on an average daily volume of 1,990,000 shares, the short-interest ratio is presently 7.4 days.
Beam Therapeutics Inc. stock logo
Beam Therapeutics (NASDAQ:BEAM) Trading Up 9% - Time to Buy?
Beam Therapeutics (NASDAQ:BEAM) Shares Up 9% - Here's Why
Beam Therapeutics Inc. stock logo
Beam Therapeutics Inc. (NASDAQ:BEAM) Shares Bought by Alliancebernstein L.P.
Alliancebernstein L.P. grew its position in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 149.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 212,804 shares of the company's stock after purch
Beam Therapeutics Inc. stock logo
JPMorgan Chase & Co. Trims Stake in Beam Therapeutics Inc. (NASDAQ:BEAM)
JPMorgan Chase & Co. lessened its holdings in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 19.6% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 513,671 shares of the company's stock after selling 125,567 shares during the
Beam Therapeutics Inc. stock logo
Norges Bank Buys Shares of 18,591 Beam Therapeutics Inc. (NASDAQ:BEAM)
Norges Bank purchased a new stake in shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 18,591 shares of the company's stock, valued at approximately $461,000. A
Beam Therapeutics Inc. stock logo
Beam Therapeutics (NASDAQ:BEAM) Reaches New 52-Week Low - Here's Why
Beam Therapeutics (NASDAQ:BEAM) Sets New 12-Month Low - Here's Why
Beam Therapeutics Inc. stock logo
HC Wainwright Reaffirms "Buy" Rating for Beam Therapeutics (NASDAQ:BEAM)
HC Wainwright reiterated a "buy" rating and set a $80.00 price target on shares of Beam Therapeutics in a report on Monday.
Beam Therapeutics (BEAM) Gets a Buy from Scotiabank
Beam Therapeutics Inc. stock logo
Vanguard Group Inc. Lowers Stake in Beam Therapeutics Inc. (NASDAQ:BEAM)
Vanguard Group Inc. trimmed its position in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 2.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,621,989 shares of the company's stock after se
Beam Therapeutics Inc. stock logo
Raymond James Financial Inc. Takes $703,000 Position in Beam Therapeutics Inc. (NASDAQ:BEAM)
Raymond James Financial Inc. bought a new position in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 28,328 shares of the company's stock, valued at approximately $703,00
Beam Therapeutics presents additional data for BEAM-302 in AATD
Beam Therapeutics Inc. stock logo
Cinctive Capital Management LP Invests $1.62 Million in Beam Therapeutics Inc. (NASDAQ:BEAM)
Cinctive Capital Management LP bought a new position in shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 65,242 shares of the company's stock,
Beam Therapeutics Inc. stock logo
Insider Selling: Beam Therapeutics Inc. (NASDAQ:BEAM) Insider Sells 5,674 Shares of Stock
Beam Therapeutics Inc. (NASDAQ:BEAM - Get Free Report) insider Christine Bellon sold 5,674 shares of the business's stock in a transaction that occurred on Tuesday, April 1st. The shares were sold at an average price of $18.35, for a total value of $104,117.90. Following the sale, the insider now owns 117,294 shares in the company, valued at approximately $2,152,344.90. This represents a 4.61 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link.
Beam Therapeutics Inc. stock logo
Beam Therapeutics Inc. (NASDAQ:BEAM) President Sells $136,413.90 in Stock
Beam Therapeutics Inc. (NASDAQ:BEAM - Get Free Report) President Giuseppe Ciaramella sold 7,434 shares of the stock in a transaction on Tuesday, April 1st. The shares were sold at an average price of $18.35, for a total transaction of $136,413.90. Following the completion of the sale, the president now directly owns 190,216 shares in the company, valued at approximately $3,490,463.60. This represents a 3.76 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.
Beam Therapeutics Inc. stock logo
Beam Therapeutics Inc. (NASDAQ:BEAM) CEO Sells $562,666.05 in Stock
Beam Therapeutics Inc. (NASDAQ:BEAM - Get Free Report) CEO John M. Evans sold 30,663 shares of the firm's stock in a transaction dated Tuesday, April 1st. The shares were sold at an average price of $18.35, for a total value of $562,666.05. Following the sale, the chief executive officer now owns 986,249 shares in the company, valued at $18,097,669.15. The trade was a 3.02 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Beam Therapeutics Inc. stock logo
Beam Therapeutics Inc. (NASDAQ:BEAM) Given Consensus Rating of "Buy" by Brokerages
Beam Therapeutics Inc. (NASDAQ:BEAM - Get Free Report) has received a consensus recommendation of "Buy" from the fourteen brokerages that are covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a hold rating, ten have given a buy rating and two have given a strong
Beam Therapeutics Inc. stock logo
Beam Therapeutics (NASDAQ:BEAM) Trading 3.7% Higher - Still a Buy?
Beam Therapeutics (NASDAQ:BEAM) Trading Up 3.7% - Should You Buy?
Beam Therapeutics Inc. stock logo
Short Interest in Beam Therapeutics Inc. (NASDAQ:BEAM) Grows By 21.7%
Beam Therapeutics Inc. (NASDAQ:BEAM - Get Free Report) was the target of a significant growth in short interest during the month of March. As of March 15th, there was short interest totalling 12,160,000 shares, a growth of 21.7% from the February 28th total of 9,990,000 shares. Based on an average trading volume of 1,580,000 shares, the short-interest ratio is currently 7.7 days. Currently, 15.3% of the company's stock are sold short.
Beam Therapeutics Inc. stock logo
Beam Therapeutics (NASDAQ:BEAM) Sets New 52-Week Low - Here's What Happened
Beam Therapeutics (NASDAQ:BEAM) Sets New 52-Week Low - Time to Sell?
Beam Therapeutics Inc. stock logo
Beam Therapeutics (NASDAQ:BEAM) Stock Price Down 10.6% - Time to Sell?
Beam Therapeutics (NASDAQ:BEAM) Stock Price Down 10.6% - Time to Sell?
Beam Therapeutics Inc. stock logo
Beam Therapeutics (NASDAQ:BEAM) Raised to Buy at Bank of America
Bank of America upgraded Beam Therapeutics from a "neutral" rating to a "buy" rating and set a $42.00 target price on the stock in a research note on Friday.
Beam Therapeutics Inc. stock logo
IQ EQ FUND MANAGEMENT IRELAND Ltd Has $799,000 Stock Position in Beam Therapeutics Inc. (NASDAQ:BEAM)
IQ EQ FUND MANAGEMENT IRELAND Ltd increased its position in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 145.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 32,198 shares of the company's stock after buying an additional 19,080 shares
Beam Therapeutics upgraded to Buy at BofA after BEAM-302 data
Get Beam Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for BEAM and its competitors with MarketBeat's FREE daily newsletter.

BEAM Media Mentions By Week

BEAM Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

BEAM
News Sentiment

0.62

0.69

Average
Medical
News Sentiment

BEAM News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

BEAM Articles
This Week

12

7

BEAM Articles
Average Week

Get Beam Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for BEAM and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:BEAM) was last updated on 5/6/2025 by MarketBeat.com Staff
From Our Partners